The goal of this clinical trial is to learn if the drug Maraviroc works to treat refractory idiopathic inflammatory myopathy (myositis) in patients who have not responded well to traditional therapies. It will also learn about how the drug affects muscle inflammation and function. The main questions it aims to answer are: Does Maraviroc reduce inflammation in the muscles? Does Maraviroc improve patients' muscle function and overall clinical symptoms? This is an open-label study, meaning researchers will give Maraviroc to all participants (there is no placebo) to see if the drug works to treat refractory myositis. Participants will: Take a 300mg Maraviroc tablet every day for 12 weeks. Undergo exams and tests with their doctors to check their muscle function, symptom improvement, and specific health markers (like enzyme levels).

Start Date01 Sep 2026

Sponsor / Collaborator

The Chinese University of Hong Kong

NCT06974084

/ Not yet recruitingPhase 2/3

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID. The main goals of the clinical study are to determine if this combination drug therapy can improve neurocognitive and physical functions in Long Covid patients, such as fatigue severity, heart rate, blood pressure, digestion, breathing, dizziness, and cognitive function. A secondary goal is to determine if biomarker levels, measured by a diagnostic test, can improve during treatment. To qualify for the trial, a subject must be an adult ≥ 18 and ≤ 65 years of age and meets the WHO-defined post-COVID-19 condition and has one or more new-onset Long Covid symptom that persist ≥ 3 months after the diagnosis of acute COVID-19 infection. A total of 252 participants will take either two daily doses of two existing medications (Maraviroc and Atorvastatin together as separate tablets) or a placebo (pills with no active ingredient) for 16 weeks. Although these medications are not yet approved for Long Covid, they are FDA-approved for use in treating other health conditions.

Start Date15 Jul 2026

Sponsor / Collaborator-

NCT06805656

/ RecruitingPhase 2IIT

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Use of Antiretrovirals

A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals. The investigators' preliminary data indicate that the use of combined strategies to mitigate the HIV proviral reservoir size among individuals with suppressive antiretroviral treatment achieved unprecedented results in the reduction of HIV DNA present in these cells and in the reduction of CD4 + and CD8 + T cell activation. Combined interventions include intensified antiretroviral treatment to mitigate residual HIV replication, use of a histone deacetylase inhibitor to interrupt viral latency, use of an anti-proliferative medication to reduce long-lived T cells that harbor HIV and a personalized dendritic cell therapy vaccine to eliminate cells with latent HIV infection or cells present in viral sanctuaries. Due to the good results obtained in the exploratory stage of the project, the investigators propose to expand it by recruiting a larger number of patients to confirm the previously obtained results and to generate new insights related to the mechanisms involved in viral latency, latency disruption and the effects of analytical treatment interruption of antiretrovirals among patients undergoing all above mentioned interventions.

Start Date15 Jul 2026

Sponsor / Collaborator

Universidade Federal De Sao Paulo

[+3]

100 Clinical Results associated with Maraviroc

100 Translational Medicine associated with Maraviroc

100 Patents (Medical) associated with Maraviroc

1,670

Literatures (Medical) associated with Maraviroc

31 Dec 2026·OncoImmunology

Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer

Article

Author: Meel, Michaël H. ; Rius-Perez, Sergio ; Montoliu, Guillermina ; Santaballa, Ana ; Martínez-Alarcón, Nuria ; Salvador-Coloma, Carmen ; Coronado, Esther ; Tolboom, Zoey J. ; Ripoll, Francisco ; Rosado-Sanz, María ; Burgos-Panadero, Rebeca ; Casals, Eloi ; Font de Mora, Jaime ; Esteve-Codina, Anna

Triple-negative breast cancer (TNBC) remains one of the most lethal breast cancer subtypes, driven by early dissemination and resistance to therapy. Here, we reveal a macrophage-centered cytokine circuit that fuels TNBC metastasis and immune evasion. Tumor cells reprogram naïve macrophages into tumor-associated macrophages (TAMs) that secrete CCL3, CCL4, CXCL2, and IL-1β, collectively promoting epithelial-to-mesenchymal transition, migration, transendothelial invasion, and lung colonization. These TAMs, in turn, convert naïve CD4⁺ T cells into FOXP3⁺ Tregs, establishing a self-reinforcing immunosuppressive niche. Pharmacological inhibition of CCR5, CXCR2, and IL1R1 with maraviroc, navarixin, and anakinra, respectively, disrupted this cytokine axis, suppressing metastatic colonization in vivo. Our findings reveal that blocking cytokine receptor signaling disrupts the pro-metastatic crosstalk between macrophages and TNBC cells, offering a clinically actionable strategy to restrain metastasis and overcome therapy resistance in TNBC.

01 Nov 2026·FREE RADICAL BIOLOGY AND MEDICINE

CKLF1 upregulation exacerbates secondary brain injury after intracerebral hemorrhage by promoting neuronal ferroptosis and oxidative stress

Article

Author: Chen, Qianxue ; Tian, Yihao ; Yang, Shangwen ; Zhang, Jianwen ; Hua, Qiuwei ; Liu, Yupei ; Jiang, Hongxiang ; Cai, Qiang ; Zhang, Xinyi

BACKGROUND:

Secondary brain injury (SBI) following spontaneous intracerebral hemorrhage (ICH) is a critical determinant of neurological outcome. It is closely associated with neuronal death, and inflammatory responses. However, current research on SBI after ICH remains limited, and effective therapeutic targets are still lacking.

METHODS:

In this study, a collagenase-induced intracerebral hemorrhage (ICH) model was employed, and experiments were conducted 24 h after hemorrhage induction. For in vitro experiments, differentiated PC12 cells were stimulated with hemin and the CKLF1 agonist peptide C27 to evaluate the potential of CKLF1 to induce neuronal ferroptosis. Mechanistically, the CKLF1 antagonist peptide C19, the CCR5 inhibitor Maraviroc (MVC), and a p38 MAPK inhibitor were applied, in combination with immunoprecipitation (Co-IP) assays and overexpression of p53 site mutation, to elucidate the molecular mechanisms underlying CKLF1-induced ferroptosis in PC12 cells. In vivo, the effects of CKLF1 knockdown on secondary brain injury after ICH were assessed using quantitative real-time PCR (qPCR), Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) analyses.

RESULTS:

Mechanistic studies revealed that CKLF1 binds to its receptor CCR5 to activate p38 MAPK, which promotes ferroptosis by regulating p53 phosphorylation and nuclear translocation, while the mutation of p53 partially reversed the effect. This signaling cascade leads to the downregulation of ferroptosis-suppressing proteins (SLC7A11 and GPX4) and the upregulation of pro-ferroptotic proteins (COX2 and ACSL4), thereby exacerbating lipid peroxidation and oxidative stress. Conversely, AAV-mediated knockdown of CKLF1 significantly suppressed this ferroptotic signaling pathway in vivo/vitro, reduced iron deposition and neuronal ferroptosis in perihematomal tissue, improved blood-brain barrier (BBB) integrity, inhibited microglial activation, and enhanced both neurological function scores and 7-day survival rates in ICH rats.

CONCLUSION:

The present study identifies CKLF1 as a previously unrecognized regulator of neuronal ferroptosis following ICH through the CCR5/p38/p53 signaling pathway. These findings provide new mechanistic insights into ICH pathogenesis and highlight CKLF1 as a promising therapeutic target for precision treatment of hemorrhagic stroke.

01 Aug 2026·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

C–C motif chemokine 3 interferes with oligodendrocyte maturation in the brain

Article

Author: Nishimura, Sakuno ; Itoh, Kouichi ; Nakane, Tatsuto ; Ishihara, Nami ; Okino, Hana ; Vogel, Christoph F A ; Ishihara, Yasuhiro ; Tominaga, Takashi

White matter alteration caused by abnormal myelination is a major contribution to the pathophysiology of autism spectrum disorder (ASD). We previously reported that mice prenatally exposed to valproic acid (VPA) showed increased expression of C-C motif chemokine ligand 3 (CCL3) in the developing hippocampus, and that antagonizing C-C chemokine receptor type 5 (CCR5), a CCL3 receptor, recovered neural circuit dysfunction. Therefore, we investigated the effects of CCL3 on oligodendrocyte differentiation. Treatment of the rat oligodendrocyte precursor cell (OPC) line CG4 and mouse primary OPC with CCL3 promoted CG4 migration. Conditioned media from BV-2 and primary microglia also promoted CG4 migration, and this promotion was cancelled by the CCR5 antagonist, maraviroc. CCL3 inhibited the differentiation of primary OPCs into mature oligodendrocytes. Therefore, microglia-derived CCL3 acts directly on OPCs by promoting their migration and inhibiting their differentiation. In organotypic whole-brain slice cultures, the expression of mature oligodendrocyte markers and the stained area of myelin basic protein (MBP) increased in a time-dependent manner. Treatment of slices with CCL3 reduced the expression of mature oligodendrocyte markers and the area of MBP staining. These changes were reversed by maraviroc pretreatment. In mice prenatally exposed to VPA, the expression of mature oligodendrocyte markers was reduced, myelin was thinner at 10 days of age, and axonal diameter was reduced at 8 weeks of age compared with control mice. These abnormalities were ameliorated by maraviroc treatment. Collectively, CCL3 interferes with oligodendrocyte maturation, thereby delaying axonal myelination and resulting in neural circuit dysfunction mediated by VPA.

News (Medical) associated with Maraviroc

24 Aug 2026

·www.medigenvac.com

MVC Accelerates Second-Generation Enterovirus Vaccine Development via Dual-Track Strategy, Partnering with Two Major Domestic CDMOs

Medigen Vaccine Biologics Corp. (MVC, 6547.TWO) today announced the official initiation of the first phase of domestic antigen process development collaboration for its “Second-Generation Multivalent Enterovirus Vaccine”. Driven by MVC’s core technological roadmap, the company has signed two independent agreements with Taiwan Bio-Manufacturing Corp. (TBMC) and TFBS Bioscience Inc. (TFBS, 6939.TWO). This parallel collaboration aims to develop antigen processes for multiple viral serotypes, accelerating development timelines and further strengthening the self-reliant development and manufacturing capabilities of Taiwan's vaccine industry. Building on the First-Generation EV-71 Vaccine to Tackle the Technical Barriers of a Second-Generation Multivalent Product As one of the few domestic vaccine manufacturers with a proven track record of successfully advancing novel vaccines from the laboratory to commercial mass production (Bench-to-Market), MVC has already achieved outstanding results in the domestic market with its first-generation enterovirus 71 (EV-71) vaccine, ENVACGEN®, of which the first batch has already been exported to Vietnam. To address the rapidly changing epidemiological patterns of enteroviruses, MVC is leveraging the success of its first-generation vaccine to invest in a broader-protection second-generation multivalent vaccine, continuing to deepen its technological barriers and laying a solid foundation for subsequent clinical development and commercialization. Leading the R&D Roadmap and Precisely Orchestrating Scarce Domestic BSL-2 Capacity Enterovirus vaccine process development requires specialized facilities compliant with stringent biosafety standards, and Biosafety Level 2 (BSL-2) facilities and production capacity are relatively scarce in Taiwan. In addition to actively constructing its own second manufacturing plant to expand long-term capacity, MVC’s collaboration with TBMC and TFBS integrates over half of Taiwan's currently available BSL-2 R&D capacity, creating a comprehensive support system for vaccine development. In this collaboration, TBMC leverages the strengths of its integrated CRDMO platform to connect R&D, analytics, process development, and GMP manufacturing. By utilizing data-driven process decisions, it helps accelerate the product’s progression toward clinical trials and commercialization. TFBS, meanwhile, has deep-rooted expertise in virology and analytical technologies and has expanded into CDMO services, with particular expertise in virus-based products. Through a clear division of expertise and the integration of resources, the three parties connect the technologies and capacities of different domestic enterprises to enhance the efficiency of vaccine development. Integrating Domestic Vaccine Development Capacity for Shared Industry Growth Leo Lee, Chief Executive Officer of MVC, stated: “To develop an internationally competitive second-generation multivalent enterovirus vaccine, the key is to elevate the technical barriers early in development. We have specifically integrated the expertise and capabilities of TBMC and TFBS, and hope that through this collaboration among domestic biopharmaceutical industry players we can accelerate the development of a new-generation vaccine. The process experience and technical achievements accumulated during this stage will also subsequently connect with MVC's second manufacturing plant, continuously expanding Taiwan's vaccine research, development, and manufacturing capabilities.” David Chang, Chief Executive Officer of TBMC, stated: “We are delighted to work with MVC to advance the development of the second-generation multivalent enterovirus vaccine. TBMC possesses facilities and a technical team that comply with PIC/S GMP standards. In this collaboration, we will contribute our high-throughput integrated process development and manufacturing capabilities to help MVC accelerate vaccine development and subsequent scale-up, jointly strengthening the resilience of Taiwan's self-reliant vaccine supply and contributing to domestic public health.” Tatung Yuan, Chief Executive Officer of TFBS, stated: “MVC’s successful experience with its first-generation EV-71 vaccine and its international market expansion demonstrate the strength of Taiwan’s vaccine research and development capabilities. TFBS is pleased to continue our long-standing collaboration with MVC and apply our expertise in virology, analytics, process development, and GMP manufacturing to support the development of this second-generation multivalent vaccine. Together, we aim to further strengthen the connectivity of Taiwan’s vaccine development ecosystem.” About Medigen Vaccine Biologics Corporation Founded in 2012, MVC is dedicated to combating infectious diseases through the development and mass production of innovative vaccines. Utilizing advanced cell-culture technology and a PIC/S GMP-certified biopharmaceutical facility, MVC notably served as the only domestic vaccine manufacturer to receive Emergency Use Authorization (EUA) in Taiwan during the COVID-19 pandemic, demonstrating its robust R&D capabilities. MVC's commercialized ENVACGEN®, an Enterovirus 71 Vaccine, has obtained regulatory approvals in Taiwan and Vietnam, with active market expansion in Southeast Asia. Building on this foundation, MVC continues to deepen its research in enterovirus vaccines by actively driving the development of a second-generation multivalent enterovirus vaccine. By aligning with global strategic partners, MVC aims to build a comprehensive enterovirus vaccine portfolio with the vision of becoming a global leader in enterovirus vaccine innovation. About Taiwan Bio-Manufacturing Corporation (TBMC) Taiwan Bio-Manufacturing Corporation (TBMC) is a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in advanced therapies, offering integrated, end-to-end solutions spanning drug discovery support and process development through commercialization.TBMC’s multi-platform capabilities include Nucleic Acids, Viral Vectors, Cell Therapies, and Biologics. By combining advanced technologies, scalable manufacturing processes, and a rigorous quality management system, TBMC provides high-quality and reliable CRDMO solutions that help clients shorten development timelines and accelerate advanced therapies toward clinical development and commercialization. TBMC is committed to becoming a trusted long-term strategic partner to the global biotech and pharmaceutical industries. About TFBS Bioscience Inc. TFBS Bioscience Inc. (TFBS) was founded in 2016 as the first contract research organization providing biological testing in Taiwan after its spin-off from Development Center for Biotechnology, a government-sponsored research institute. TFBS has established strong track records in several regulatory submissions, winning trust from the international regulatory agencies and biopharmaceutical industry. TFBS has launched the first viral vector contract development and manufacturing facility in Taiwan, providing fully integrated end-to-end contract development and manufacturing services for the needs of clinical trials. TFBS offers manufacturing expertise in adeno-associated virus, lentivirus, and retrovirus. With the customization specialty and state-of-the-art facility, TFBS is the best partner offering clients a one-stop-shop solution for gene and cell therapy.

VaccineDrug ApprovalClinical StudyEmergency Use Authorization

06 Aug 2026

·www.biospace.com

Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data

$40 Million financing round led by existing investors AMR Action Fund and BNP Paribas Asset Management Alts, consisting of approximately $18M in 1Q and $22M in 2Q Additional $20 Million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the RESTORATiVE303 Phase 3 study of VE303 for recurrent C. difficile infection Funds will support the RESTORATiVE303 study, with topline efficacy data expected in 1H 2027 RESTORATiVE303 Phase 3 study has crossed the 80% enrollment mark and is on track to complete enrollment in 2026 ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Dr. Manos Perros appointed as Executive Chairman of the Board and Andrew Davis joins as independent Board Director CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences , a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced securing $60 million in funding, a clinical update for its pivotal Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection, and new appointments to its Board of Directors. The funding includes a $40 million financing round led by existing investors AMR Action Fund and BNP Paribas Asset Management Alts , consisting of approximately $18M in 1Q and $22M in 2Q. In addition, the company has received an additional $20 million under its existing contract with BARDA to continue the RESTORATIVE303 study. The proceeds of this financing will support the Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection, with topline efficacy data expected in 1H 2027. Earlier this year, Vedanta announced that the independent Data Monitoring Committee (DMC) overseeing RESTORATiVE303 completed its first prespecified interim analysis and recommended that the study continue without modification, having determined that efficacy to date exceeded the prespecified futility threshold and that no significant adverse events or new safety signals had emerged. The trial, which is enrolling patients across more than 150 sites in approximately 20 countries, recently crossed the 80% enrollment mark. Vedanta anticipates completing enrollment of the RESTORATiVE303 study in the second half of 2026, and obtaining topline efficacy data in the first half of 2027. In connection with the financing, Vedanta also announced additions to its Board of Directors. Manos Perros, Ph.D. has been appointed Executive Chairman and Andrew Davis has joined as a new independent Board Director. Dr. Perros is a biopharmaceutical executive with over 30 years of life sciences research and development experience, most recently serving as Chief Executive Officer of Entasis Therapeutics, where he oversaw the development of Xacduro, which was approved by FDA as the first targeted treatment for Acinetobacter baumannii pneumonia, and Nuzolvence, approved by FDA as a first-in-class oral antibiotic for gonorrhea. Dr. Perros has also held senior leadership roles at AstraZeneca, Novartis, and Pfizer, where he led the program resulting in the approval of Selzentry, a first-in-class HIV treatment. Mr. Davis has more than two decades of experience executing complex commercial and strategic transactions across the biopharmaceutical industry in gastroenterology, infectious disease, and beyond. He currently serves as Chief Business and Strategy Officer at Convergent Therapeutics. Prior to Convergent, he served as Chief Business Officer at Dynavax, where he led the company’s sale to Sanofi. Prior to Dynavax, he was the Chief Business Officer at Ironwood Pharmaceuticals, Chief BD/M&A Officer at iNova Pharmaceuticals, and Senior VP of Business Development at Bausch Health, where he led the acquisitions of Salix Pharmaceuticals, Dendreon, and Bausch + Lomb. Additionally, Mr. Davis previously served on the board of infectious disease specialist Utility Therapeutics prior to its sale to Alembic Pharmaceuticals. “We are grateful to our shareholders and BARDA for their continued support and pleased to welcome Manos and Andrew to the Vedanta Board of Directors. Manos and Andrew bring a wealth of experience in development and regulatory approval of innovative drugs as well as execution of strategic transactions”, said Bernat Olle, Ph.D., founder and Chief Executive Officer of Vedanta Biosciences. About RESTORATiVE303 RESTORATiVE303 is a randomized, double-blind, placebo-controlled, multinational Phase 3 clinical trial evaluating the safety and efficacy of VE303 in patients at high risk for recurrence of Clostridioides difficile infection (CDI) following a course of antibiotics for a prior CDI episode. The primary endpoint is the CDI recurrence rate at Week 8 in the VE303 and placebo groups. Participants are randomized 2:1 to receive a 14-day course of VE303 or matching placebo. The study is enrolling patients who are experiencing recurrent CDI, including many with first recurrence and a significant proportion receiving fidaxomicin for their qualifying CDI episode, reflecting the evolving standard of care in CDI management. The RESTORATiVE303 trial is intended to form the basis for a Biologics License Application (BLA) to be submitted to the U.S. Food and Drug Administration (FDA). About VE303 VE303 is an orally administered, potential first-in-class live biotherapeutic product (LBP) for the prevention of recurrent Clostridioides difficile infection (CDI). It consists of a defined bacterial consortium of eight strains that were rationally selected using Vedanta’s product engine. VE303 is produced from pure, clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypass the need to rely on donor fecal material of inconsistent composition. VE303 has received Orphan Drug Designation (2017) and Fast Track Designation (2023) from the FDA. This project has been supported in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50120C00177. About Recurrent C. difficile Infection Clostridioides difficile infection is a potentially life-threatening gastrointestinal infection affecting up to 175,000 patients annually in the United States, resulting in approximately 20,000 deaths each year. Patients who experience an initial CDI episode are at significant risk of recurrence, with each recurrence increasing the likelihood of subsequent episodes. Recurrent CDI is associated with substantial morbidity, prolonged hospitalization, and diminished quality of life. There remains a significant unmet need for safe and effective therapies that address the underlying dysbiosis driving recurrence. About Vedanta Biosciences Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is currently being evaluated in the global Phase 3 RESTORATiVE303 registrational study for the prevention of recurrent C. difficile infection. Contacts Media Ten Bridge Communications TBCVedanta@tenbridgecommunications.com Investors Chris Brinzey +1 617-835-9304 Chris.Brinzey@icrhealthcare.com

05 Apr 2026

·www.sciencedaily.com

Scientists find hidden brain cells helping deadly cancer grow

Scientists in Canada have uncovered a surprising weakness in glioblastoma, one of the deadliest brain cancers. They found that certain brain cells—once believed to only support healthy nerves—can actually help tumors grow by sending signals that strengthen cancer cells. When researchers blocked this communication, tumor growth slowed dramatically in lab models.A team of researchers in Canada has identified a new way to slow the growth of glioblastoma, the most aggressive and currently incurable type of brain cancer, and they have also pointed to an existing drug that could potentially be used to treat it. The study reveals that some brain cells, previously believed to only support normal nerve function, can actually assist glioblastoma in growing and spreading. These cells send signals that strengthen tumor cells. When scientists blocked this communication in laboratory models, tumor growth dropped significantly. The findings also highlight a potential treatment opportunity. Researchers found that a drug already used to treat HIV might be able to interfere with this process, offering a new option for patients who currently have very limited treatment choices. Glioblastoma has a poor outlook, with survival often measured in months. Study Details and Research Teams The research was published Neuron and conducted by scientists at McMaster University and The Hospital for Sick Children (SickKids). The co-first authors are Kui Zhai, a research associate in the Singh Lab at McMaster, and Nick Mikolajewicz, who was a postdoctoral fellow in the Moffat Lab at SickKids during the study. "Glioblastoma isn't just a mass of cancer cells, it's an ecosystem," says Sheila Singh, co-senior author of the study and professor of surgery at McMaster University. "By decoding how these cells talk to each other, we've found a vulnerability that could be targeted with a drug that's already on the market," adds Singh, who is also director of the Centre for Discovery in Cancer Research at McMaster. Oligodendrocytes and Tumor Communication Scientists have long known that glioblastoma relies on networks of interacting cells to grow. Interrupting these connections can slow the disease. This study focused on identifying which specific brain cells are involved. The team found that oligodendrocytes, which normally protect nerve fibers, can change their behavior and begin supporting tumor growth. These cells communicate with cancer cells through a defined signaling system, creating conditions that help the tumor survive and expand. When this signaling was blocked in lab models, tumor growth slowed considerably, showing how essential this interaction is. Existing HIV Drug Offers New Hope A key part of this signaling process involves a receptor called CCR5. This receptor is already targeted by an HIV drug known as Maraviroc. Because this medication is already approved and widely used, it could potentially be repurposed more quickly as a treatment for glioblastoma. "The cellular ecosystem within glioblastoma is far more dynamic than previously understood. In uncovering an important piece of the cancer's biology, we also identified a potential therapeutic target that could be addressed with an existing drug. This finding opens a promising path to explore whether blocking this pathway can speed progress toward new treatment options for patients," said Jason Moffat, co-senior author of the study, senior scientist and head of the Genetics & Genome Biology program at SickKids. Building on Earlier Discoveries These findings build on earlier work by Singh and Moffat published in Nature Medicine in 2024, which showed that cancer cells can take advantage of pathways normally used during brain development to spread. Together, these studies point toward a new direction in glioblastoma research focused on disrupting the communication systems that tumors rely on. The research was supported by the 2020 William Donald Nash Brain Tumour Research Fellowship and the Canadian Institutes for Health Research. Singh is a Tier 1 Canada Research Chair in Human Cancer Stem Cell Biology, and Moffat holds the GlaxoSmithKline Chair in Genetics & Genome Biology at The Hospital for Sick Children.

100 Deals associated with Maraviroc

External Link

KEGG	Wiki	ATC	Drug Bank
D06670	Maraviroc	J05AX09	DB04835

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	06 Aug 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fatty Liver	Phase 3	United Kingdom	ViiV Healthcare Ltd.	01 Mar 2017
Metabolic dysfunction-associated steatotic liver disease	Phase 3	United Kingdom	ViiV Healthcare Ltd.	01 Mar 2017
AIDS Dementia Complex	Phase 3	United States	ViiV Healthcare Ltd.	01 Jun 2015
Cardiovascular Diseases	Phase 3	United States	Pfizer Inc.	01 Jan 2010
Inflammation	Phase 3	United States	Pfizer Inc.	01 Jan 2010
Acquired Immunodeficiency Syndrome	Phase 3	Brazil	ViiV Healthcare Ltd.	01 Jul 2007
Acquired Immunodeficiency Syndrome	Phase 3	Brazil	Pfizer Inc.	01 Jul 2007
COVID-19	Phase 2	Spain	ViiV Healthcare Ltd.	26 Jun 2020
Metabolic Dysfunction Associated Steatohepatitis	Phase 2	Germany	ViiV Healthcare Ltd.	23 May 2018
AIDS-related Kaposi Sarcoma	Phase 2	United States	Pfizer Inc.	09 Mar 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT07080567 (MASTER, Pubmed \| BMJ Open)	Phase 2	Ischemic stroke	80	Maraviroc	zljbwahqpd(wyvvtvpwbe) = motor learning skills and plasticity in the peri-infarct region assessed using MRI connectivity and spectroscopy at 90 days qcvnyvunrk (qikqdinuvl )	Positive	01 Apr 2026
NCT05932550 (Pubmed)	Phase 2	Depressive Disorder Add-on CCR5	10	Maraviroc 300 mg	ehvhbwnkem(riigjfxffv) = hqyfjyutux mclzzvraxe (jwdxrgcgyw, 9.3)	Positive	06 Jun 2024
NCT02881762 (MAVERIC, CTgov)	Phase 4	HIV Infections \| Hepatitis C	10	Maraviroc (Maraviroc)	ffkaqxoktu(lhevhqujxs) = lctohyrkab wdqocffqtf (gjbsauwacj, 1012880) View more	-	01 May 2024
				Maraviroc (No Maraviroc)	ffkaqxoktu(lhevhqujxs) = nuqcctexgi wdqocffqtf (gjbsauwacj, 1411027) View more
NCT04435522 (CTgov)	Phase 1	COVID-19	9	maraviroc	ezovviypgg = znvzakqciz ijagbqmjbj (nzielaymxh, ncbakznotc - ottjbyjjcx) View more	-	29 Apr 2024
NCT02741323 (CTgov)	Phase 2	Kidney Diseases \| HIV Infections	97	maraviroc (Arm 1: Maraviroc (MVC))	rmzxhctxuz(jyduprgwsp) = tixtdqvsvm xqeasryiou (zvxwbrbggo, wtbecvsdeg - obgrpsavip) View more	-	21 Aug 2023
				Placebo (Arm 2: Placebo)	rmzxhctxuz(jyduprgwsp) = wabnawydxu xqeasryiou (zvxwbrbggo, ojapzrjwnn - mdkbjyyfpp) View more
NCT00948753 (CTgov)	Phase 1/2	Hematopoietic stem cell transplantation \| Graft vs Host Disease	38	Maraviroc 150 MG (Phase 1: 150mg Maraviroc)	teogtrdbff = ykgpahlgjv edtnocthet (hbmoroywje, lquimxurbq - jnlkricaak) View more	-	17 May 2022
				Maraviroc 300 mg (Phase 1: 300mg Maraviroc)	teogtrdbff = huxhgsccbw edtnocthet (hbmoroywje, zjljtteixt - bjfpldymfl) View more
NCT02519777 (CTgov)	Phase 4	Cognitive Dysfunction \| HIV Infections	191	Placebo for dolutegravir (DTG) (Arm A: Placebo MVC and Placebo DTG)	hgegeepfsl(gjvlgcousk) = npkpglebeo ftoyvmphbc (fbdzylinby, wurnygldnc - oahtnlapog) View more	-	02 Mar 2022
				Placebo for maraviroc (MVC)+Dolutegravir (DTG) (Arm B: DTG and Placebo MVC)	hgegeepfsl(gjvlgcousk) = tqfeivrxzv ftoyvmphbc (fbdzylinby, ikkldvdeqd - dizjvmwmei) View more
NCT03172026 (MAROS, CTgov)	Phase 2/3	Stroke	2	Rehabilitation therapy+Maraviroc 300 mg (Maraviroc + Augmented Rehabilitation)	mazqmnqmpu(watmsbwdtv) = dedsbavjxz ojjjsyyikv (kulskcwhhr, mgydhburbq - elshippxit) View more	-	03 Aug 2021
				Placebo 300 mg (Placebo + Augmented Rehabilitation)	mazqmnqmpu(watmsbwdtv) = pggxsbidob ojjjsyyikv (kulskcwhhr, qfvxhcuehz - uxtbotbkzs) View more
NCT03274804 (PICCASSO, CTgov)	Phase 1	Spinocerebellar Degenerations \| Metastatic Microsatellite Stable Colorectal Carcinoma \| Metastatic Colorectal Carcinoma	20	Pembrolizumab+maraviroc	fkagoclfnz = bidzwcfcas yvwppibiop (scmokkcqlm, lticlhgabd - bkzklmgxdi) View more	-	22 Apr 2021
NCT01276236 (CTgov)	Phase 2	AIDS-related Kaposi Sarcoma	13	maraviroc	hpyoblhrwy = weemjcsgir ultiksfgev (kewopirxzf, kkghujpitu - bngtpleuky) View more	-	05 Mar 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis